Source:http://linkedlifedata.com/resource/pubmed/id/12002701
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2002-5-10
|
| pubmed:abstractText |
MS-209 is a newly synthesised multidrug-resistance (MDR)-reversing agent with few side-effects. In this study, we evaluated the effect of MS-209 on P-glycoprotein (Pgp)-positive tumours in mice by means of technetium-99m methoxyisobutylisonitrile (MIBI) imaging. Mice received Pgp-negative KB-3-1 or Pgp-positive KB-C1 cell xenografts. KB-3-1-bearing mice were administered 0 or 100 mg/kg of MS-209 (groups S0 and S100, respectively), and KB-C1-bearing mice 0, 50, 100 or 200 mg/kg (groups R0, R50, R100 and R200, respectively), 30 min before imaging studies. Dynamic 99mTc-MIBI images were acquired for 30 min, followed by biodistribution studies. Washout of 99mTc-MIBI from the tumours was faster in group R0 than in group S0 on visual analysis, and the washout half-time estimated by region of interest analysis was shorter in group R0 than in group S0. Biodistribution studies revealed that 99mTc-MIBI accumulation in tumours (expressed as %ID/g) was also lower in group R0 than in group S0. MS-209 delayed the 99mTc-MIBI washout from KB-C1 tumours. Washout half-time was longer in groups R50, R100 and R200 than in group R0. A higher %ID/g was observed in groups R100 and R200 than in group R0. In KB-3-1 tumours, MS-209 had no effect on the washout half-time or the %ID/g. This study demonstrated that MS-209 increases the 99mTc-MIBI accumulation in Pgp-positive tumours. The MDR-reversing effect of MS-209 could be effectively evaluated with 99mTc-MIBI visually and non-invasively in vivo. 99mTc-MIBI imaging with MS-209 prior to chemotherapy should contribute significantly to the treatment strategy in patients with multidrug-resistant tumours.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Radiopharmaceuticals,
http://linkedlifedata.com/resource/pubmed/chemical/Technetium Tc 99m Sestamibi,
http://linkedlifedata.com/resource/pubmed/chemical/dofequidar
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1619-7070
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
29
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
288-94
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12002701-Animals,
pubmed-meshheading:12002701-Carcinoma, Squamous Cell,
pubmed-meshheading:12002701-Drug Resistance, Multiple,
pubmed-meshheading:12002701-Drug Resistance, Neoplasm,
pubmed-meshheading:12002701-Female,
pubmed-meshheading:12002701-Gene Expression,
pubmed-meshheading:12002701-Genes, MDR,
pubmed-meshheading:12002701-Humans,
pubmed-meshheading:12002701-KB Cells,
pubmed-meshheading:12002701-Mice,
pubmed-meshheading:12002701-Mice, Inbred BALB C,
pubmed-meshheading:12002701-Mice, Nude,
pubmed-meshheading:12002701-Neoplasm Transplantation,
pubmed-meshheading:12002701-P-Glycoprotein,
pubmed-meshheading:12002701-Quinolines,
pubmed-meshheading:12002701-Radiopharmaceuticals,
pubmed-meshheading:12002701-Reproducibility of Results,
pubmed-meshheading:12002701-Sensitivity and Specificity,
pubmed-meshheading:12002701-Technetium Tc 99m Sestamibi,
pubmed-meshheading:12002701-Tissue Distribution
|
| pubmed:year |
2002
|
| pubmed:articleTitle |
Evaluation of MS-209, a novel multidrug-resistance-reversing agent, in tumour-bearing mice by technetium-99m-MIBI imaging.
|
| pubmed:affiliation |
Division of Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Japan. tatsumi@tracer.med.osaka-u.ac.jp
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Evaluation Studies
|